DrugPatentWatch Database Preview
Emd Serono Inc Company Profile
What is the competitive landscape for EMD SERONO INC, and what generic alternatives to EMD SERONO INC drugs are available?
EMD SERONO INC has five approved drugs.
There are five US patents protecting EMD SERONO INC drugs.
There are one hundred and thirty-six patent family members on EMD SERONO INC drugs in thirty-seven countries and fifty-two supplementary protection certificates in fifteen countries.
Summary for Emd Serono Inc
| International Patents: | 136 |
| US Patents: | 5 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 5 |
| Drug Master File Entries: | 2 |
Drugs and US Patents for Emd Serono Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emd Serono Inc | GLUCOPHAGE XR | metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021202-001 | Oct 13, 2000 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-001 | Sep 26, 1997 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Emd Serono Inc | MAVENCLAD | cladribine | TABLET;ORAL | 022561-001 | Mar 29, 2019 | RX | Yes | Yes | 8,785,415 | Start Trial | Y | Start Trial | |||
| Emd Serono Inc | GLUCOPHAGE XR | metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021202-004 | Apr 11, 2003 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Emd Serono Inc | CETROTIDE | cetrorelix | INJECTABLE;INJECTION | 021197-002 | Aug 11, 2000 | DISCN | No | No | 6,319,192 | Start Trial | Start Trial | ||||
| Emd Serono Inc | GLUCOPHAGE | metformin hydrochloride | TABLET;ORAL | 020357-004 | Nov 5, 1998 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Emd Serono Inc | GLUCOPHAGE | metformin hydrochloride | TABLET;ORAL | 020357-002 | Mar 3, 1995 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Emd Serono Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Emd Serono Inc | GEREF | sermorelin acetate | INJECTABLE;INJECTION | 020443-002 | Sep 26, 1997 | 4,703,035 | Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix | INJECTABLE;INJECTION | 021197-001 | Aug 11, 2000 | 7,605,121 | Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix | INJECTABLE;INJECTION | 021197-001 | Aug 11, 2000 | 4,800,191 | Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix | INJECTABLE;INJECTION | 021197-002 | Aug 11, 2000 | 6,863,891 | Start Trial |
| Emd Serono Inc | GLUCOPHAGE XR | metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021202-004 | Apr 11, 2003 | 6,475,521 | Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix | INJECTABLE;INJECTION | 021197-002 | Aug 11, 2000 | 7,605,121 | Start Trial |
| Emd Serono Inc | CETROTIDE | cetrorelix | INJECTABLE;INJECTION | 021197-002 | Aug 11, 2000 | 6,319,192 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Emd Serono Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 1787809 | Start Trial |
| Brazil | PI0408848 | Start Trial |
| Denmark | 1608344 | Start Trial |
| Japan | 2002512975 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2004087100 | Start Trial |
| Japan | 5795456 | Start Trial |
| Lithuania | PA2018502 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Emd Serono Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1506211 | CA 2014 00037 | Denmark | Start Trial | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116 |
| 1412357 | CA 2008 00035 | Denmark | Start Trial | PRODUCT NAME: SITAGLIPTIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER MONOPHOSPHAT, METFORMIN VALGFRIT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER HYDROCHLORID |
| 2805723 | LUC00064 | Luxembourg | Start Trial | PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824 |
| 1412357 | 50/2008 | Austria | Start Trial | PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE ALS MONOPHOSPHAT, UND METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REGISTRATION: CH 58450 01-03 20080408 |
| 1608344 | LUC00065 | Luxembourg | Start Trial | PRODUCT NAME: CLADRIBINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1212 20170824 |
| 1506211 | C01506211/02 | Switzerland | Start Trial | PRODUCT NAME: DAPAGLIFLOZIN + METFORMIN; REGISTRATION NO/DATE: SWISSMEDIC 65377 16.07.2015 |
| 1827461 | 9/2018 | Austria | Start Trial | PRODUCT NAME: CLADRIBIN; REGISTRATION NO/DATE: EU/1/17/1212 20170824 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
